Template:Potassium channel blocker: Difference between revisions
Content deleted Content added
<noinclude> {{template reference list}} </noinclude> |
←Blanked the page |
||
| Line 1: | Line 1: | ||
===Potassium channel blocker=== |
|||
{| class="wikitable" |
|||
|- |
|||
!Class |
|||
!Known as |
|||
!Examples |
|||
!Mechanism |
|||
!Clinical uses <ref name=Rangunless> Unless else specified in boxes, then ref is: {{cite book |author=Rang, H. P. |title=Pharmacology |publisher=Churchill Livingstone |location=Edinburgh |year=2003 |pages= |isbn=0-443-07145-4 |oclc= |doi=}} </ref> |
|||
|- |
|||
!Ia |
|||
|fast-channel blockers |
|||
| |
|||
*[[Quinidine]] |
|||
*[[Procainamide]] |
|||
*[[Disopyramide]] |
|||
| [[sodium channel|(Na<sup>+</sup>) channel]] block (intermediate association/dissociation) |
|||
| |
|||
*[[Ventricular arrhythmia]]s |
|||
*prevention of paroxysmal [[recurrent atrial fibrillation]] (triggered by [[vagus nerve|vagal]] overactivity), *procainamide in [[Wolff-Parkinson-White syndrome]] |
|||
|- |
|||
!Ib |
|||
| |
|||
| |
|||
*[[Lidocaine]] |
|||
*[[Phenytoin]] |
|||
*[[Mexiletine]] |
|||
| [[sodium channel|(Na<sup>+</sup>) channel]] block (fast association/dissociation) |
|||
| |
|||
*treatment and prevention during and immediately after [[myocardial infarction]], though this practice is now discouraged given the increased risk of [[asystole]] |
|||
**[[ventricular tachycardia]] |
|||
**[[atrial fibrillation]] |
|||
|- |
|||
!Ic |
|||
| |
|||
| |
|||
*[[Flecainide]] |
|||
*[[Propafenone]] |
|||
*[[Moricizine]] |
|||
|[[sodium channel|(Na<sup>+</sup>) channel]] block (slow association/dissociation) |
|||
| |
|||
*prevents [[paroxysmal atrial fibrillation]] |
|||
*treats [[recurrent tachyarrhythmias]] of abnormal [[Electrical conduction system of the heart|conduction system]]. |
|||
|- |
|||
!II |
|||
|Beta-blockers |
|||
| |
|||
*[[Propranolol]] |
|||
*[[Esmolol]] |
|||
*[[Timolol]] |
|||
*[[Metoprolol]] |
|||
*[[Atenolol]] |
|||
| [[beta blocker|beta blocking]] |
|||
| |
|||
*decrease [[myocardial infarction]] mortality |
|||
*prevent recurrence of [[tachyarrhythmia]]s |
|||
|- |
|||
!III |
|||
| |
|||
| |
|||
*[[Amiodarone]] |
|||
*[[Sotalol]] |
|||
*[[Ibutilide]] |
|||
*[[Dofetilide]] |
|||
*[[E-4031]] |
|||
| [[Potassium channel blocker|K<sup>+</sup> channel blocker]] |
|||
[[Sotalol]] is also a [[beta blocker|beta blocker]]<ref name="pmid11350865">{{cite journal |author=Kulmatycki KM, Abouchehade K, Sattari S, Jamali F |title=Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat |journal=Br. J. Pharmacol. |volume=133 |issue=2 |pages=286–94 |year=2001 |month=May |pmid=11350865 |pmc=1572777 |doi=10.1038/sj.bjp.0704067 |doi=10.1038/sj.bjp.0704067}}</ref> |
|||
| |
|||
*In [[Wolff-Parkinson-White syndrome]] |
|||
*(sotalol:) [[ventricular tachycardias]] and [[atrial fibrillation]] |
|||
*(Ibutilide:) [[atrial flutter]] and [[atrial fibrillation]] |
|||
|- |
|||
!IV |
|||
|slow-channel blockers |
|||
| |
|||
*[[Verapamil]] |
|||
*[[Diltiazem]] |
|||
|[[calcium channel|Ca<sup>2+</sup> channel]] block |
|||
| |
|||
*prevent recurrence of [[paroxysmal supraventricular tachycardia]] |
|||
*reduce [[ventricular rate]] in patients with [[atrial fibrillation]] |
|||
|- |
|||
!V |
|||
| |
|||
| |
|||
*[[Adenosine]] |
|||
*[[Digoxin]] |
|||
|Work by other or unknown mechanisms (Direct nodal inhibition). |
|||
|Used in supraventricular arrhythmias, especially in Heart Failure with Atrial Fibrillation, contraindicated in ventricular arrhythmias. |
|||
|- |
|||
|} |
|||
<noinclude> |
|||
{{template reference list}} |
|||
</noinclude> |
|||